Medicines Australia welcomes the successful appointment of four newly elected Board Directors and two re-elected Board Directors.
Chair of Medicines Australia, Dr Anna Lavelle, congratulated the six Board members.
“I am pleased to announce that Stuart Knight and James McDonnell have successfully been re-elected to the Medicines Australia Board and warmly welcome the appointment of new Directors; Josie Downey, Lizzie Marett, Nathalie McNeil and Prashant Nikam,” Dr Lavelle said.
“The appointment of these Board Directors comes at a pivotal time for Medicines Australia and our sector. Their deep industry knowledge and breadth of experiences will be a great benefit to ensure our industry can deliver better health outcomes for Australians.
“I would like to thank all the recently departed Board Directors for their significant service and contribution to the success of our organisation and the health system as a whole.
“I also wish to specifically acknowledge Selected Director, Bruce Goodwin, who has announced his retirement from the Board. I have worked closely with Bruce for many years and his wisdom and steadfast advice has been valued by all,” Dr Lavelle said.
“In the new year, the Board will start the search for a new Selected Director,” she added.
The six Directors will join the existing Board, bringing the current membership to eleven:
- Dr Anna Lavelle (Chair)
- Adam Roach (BeiGene)
- Anne Harris (Pfizer)
- Ashraf Al-Ouf (Bayer)
- James McDonnell (CSL Vifor) – re-appointed
- Josie Downey (Merck Healthcare) – new appointment
- Lizzie Marrett (Astellas) – new appointment
- Nathalie McNeil (AbbVie) – new appointment
- Patrick Desbiens (GSK)
- Prashant Nikam (MSD) – new appointment
- Stuart Knight (Roche Products) – re-appointed
CEO of Medicines Australia, Elizabeth de Somer, in welcoming the Board Directors, said it is a crucial time for health reform and improving patient access to innovative medicines.
“Medicines Australia is thrilled to welcome our newest and re-elected Board Directors at such a significant time in our country’s health system history,” Ms de Somer said.
“Under the Chair’s guidance, the Board have set us in good stead to shape health policy and reform our system for the future
“The strategic guidance from the Board will focus our efforts on ensuring Australia prioritises patients access to innovative medicines, treatments and vaccines,” Ms de Somer said.
Source: Medicines Australia
